Dea Belazi, PharmD, Vice President, Payer & Healthcare Solutions, Source Healthcare Analytics, says that medication adherence is a major keystone that allows a patient to achieve better outcomes in any therapeutic area.
Dea Belazi, PharmD, Vice President, Payer & Healthcare Solutions, Source Healthcare Analytics, says that medication adherence is a major keystone that allows a patient to achieve better outcomes in any therapeutic area. He notes that medication adherence is part of the pharmacy benefit manager's (PBM) business model to make sure patients have access to their medications. "Being able to have a patient that's adherent does support the business model for PBM as it relates to getting access to meds whether it's through retail, specialty, mail order pharmacies, etcetera," said Dr Belazi.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More